Brii Biosciences Limited
2137.HK
Hong Kong Stock Exchange1.04
HKD
-0.03
- -
Brii Biosciences Limited
2137.HK
(Hong Kong Stock Exchange)
Recent
price
1.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Brii Biosciences Limited Brii Biosciences Limited (2137.HK) is a biotechnology company that develops innovative therapies targeting infectious diseases, including chronic hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensively drug-resistant (XDR) gram-negative bacterial infections, and central nervous system disorders; its lead HBV functional cure portfolio comprises the recombinant protein-based immunotherapeutic BRII-179, the HBV-targeting siRNA elebsiran (previously BRII-835), and the neutralizing monoclonal antibody tobevibart (previously BRII-877), alongside HIV long-acting candidates BRII-732 and BRII-753, the synthetic lipopeptide BRII-693 for MDR/XDR gram-negative infections, and epetraborole (previously BRII-658) for nontuberculous mycobacterial (NTM) lung disease. Founded in 2017 and headquartered in Beijing, China, with additional operations in the United States including Durham, North Carolina, and San Mateo, California, the company primarily operates in Greater China while holding global rights to select assets and pursues clinical development through in-house research, strategic partnerships, and collaborations with organizations such as Vir Biotechnology and Joincare Pharmaceutical Group Industry Co., Ltd. Brii Biosciences targets patients with high unmet needs in the world's largest HBV market in China and advances multiple Phase 2 trials including ENSURE (elebsiran plus pegylated interferon alpha), ENRICH (BRII-179 sequential with elebsiran and pegylated interferon alpha), and ENHANCE (triple combination of BRII-179, elebsiran, and pegylated interferon alpha), all of which received Breakthrough Therapy Designation from China's NMPA. In recent developments, the company completed enrollment in the ENHANCE study in January 2025 and anticipates key data readouts from ongoing HBV trials through 2025-2026; secured full intellectual property rights to BRII-179 via an asset purchase from VBI Vaccines in December 2024 for US$18 million, eliminating future royalties; entered a strategic licensing agreement with Joincare Group in July 2025 for soralimixin (BRII-693) development and commercialization in Greater China; received IND approval from China's CDE in October 2024 for a Phase 1 pharmacokinetic bridging study of BRII-693; and initiated a HK$60 million share buyback program in December 2024.